NeoTYPE® Discovery Profile for Solid Tumors
GTR Test Accession: Help GTR000558437.2
CAP
Last updated in GTR: 2020-01-29
Last annual review date for the lab: 2022-12-27 Past due LinkOut
At a Glance
Prognostic; Therapeutic management
Solid tumor
ABL1 (9q34.12), ABL2 (1q25.2), ACVR1B (12q13.13), ADGRA2 (8p11.23), AKT1 (14q32.33), ...
Biochemical Genetics - Immunohistochemistry: Protein Expression; ...
Not provided
Not provided
Guidance for selecting a drug therapy and/or dose
Ordering Information
Offered by: Help
Specimen Source: Help
Who can order: Help
  • Licensed Physician
Contact Policy: Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order: Help
Test service: Help
Clinical Testing/Confirmation of Mutations Identified Previously
Pharma Services
Result interpretation
Informed consent required: Help
Decline to answer
Pre-test genetic counseling required: Help
Decline to answer
Post-test genetic counseling required: Help
Decline to answer
Recommended fields not provided:
Conditions Help
Total conditions: 1
Condition/Phenotype Identifier
Test Targets
Genes Help
Total genes: 315
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Methodology
Total methods: 3
Method Category Help
Test method Help
Instrument *
Immunohistochemistry
Protein Expression
Fluorescence in situ hybridization (FISH)
Fluorescence in situ hybridization (FISH)
Sequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
* Instrument: Not provided
Clinical Information
Test purpose: Help
Prognostic; Therapeutic management
Clinical utility: Help
Guidance for selecting a drug therapy and/or dose
View citations (1)
  • The NeoTYPE™ Discovery Profile for Solid Tumors is a 326 test profile that combines NGS, FISH and IHC to allow for the accurate and sensitive detection of genomic alterations in the genes most relevant to various solid tumor cancers. These genomic alterations include SNP's, indels, rearrangements and other alterations. Testing can aid in the diagnosis of various diseases and provide information to develop strategies for the treatment and management of the underlying disease. In addition, the results obtained from the NeoTYPE™ Discovery Profile for Solid Tumors can also be used in current or future clinical research projects.

Recommended fields not provided:
Technical Information
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
SNV - Sensitivity: 98.8%, Specificity: >99.9%; Indel - Sensitivity: 100%, Specificity: >99.9%; CNV - Sensitivity: 95%, Specificity: >99.9%
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
Yes

Method used for proficiency testing: Help
Intra-Laboratory

PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
Recommended fields not provided:
Regulatory Approval
FDA Review: Help
Not provided
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.